Transfer Factor

Kirkpatrick, Charles H.; Burger, Denis R.

doi:10.3109/10408368009108727

Cited by 8 publications

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma

Miller¹,

S̄pitler²,

Allen³

et al. 1988

Cancer

View full text Add to dashboard Cite

One hundred and sixty-eight evaluable patients participated in a randomized, double-blind study of transfer factor (TF) versus placebo as surgical adjuvant therapy of Stage I and Stage II malignant melanoma. Eighty-five patients received TF prepared from the leukocytes of healthy volunteer donors; eighty-three participants received placebo. Therapy was initiated within 90 days of resection of all evident tumor and continued until 2 years of disease-free survival or the occurrence of unresectable dissemination of melanoma. Known prognostic variables were similarly distributed in the treatment and control groups, documenting the randomization efficacy. Three endpoints were analyzed: disease-free interval, time to Stage III metastasis, and survival. After a median follow-up period of 24.75 months, there was a trend in favor of the placebo group with regard to all three endpoints and this was significant (P less than or equal to 0.05) for time to Stage III metastasis. These findings indicate that TF is not effective as surgical adjuvant therapy of malignant melanoma.

show abstract

A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma

Miller¹,

S̄pitler²,

Allen³

et al. 1988

Cancer

View full text Add to dashboard Cite

show abstract

Some properties and protective activity of specific DLE against Salmonella cholerae suis infection

Arnaudov¹,

Tziporkov

1996

Biotherapy

View full text Add to dashboard Cite

From a rabbit lymphoid tissue, twice immunized with a Salmonella ch. suis vaccine, was obtained a dialysable leucocyte extract (DLE) (m. w. 10,000Da; protein content 1.14 mg/ml; content of ribose 2.7 mg/ml; A260/A280 ratio 2.17 and pH 6.8). By gel filtration on Sephadex G-25, six peaks were obtained and activity was found in peak IV. The activity of the extract was determined by a dermo-application test (DAT) on 10 cows. The protective effect was tested by a challenge with Salmonella ch. suis and Salmonella dublin pathogen strains on white mice intraperitoneally treated with DLE. The DAT proved to be positive in 8 of the 10 cows. When applied on white mice, it induced a high specific protective effect against Salmonella ch. suis (70%), but not against Salmonella dublin infection.

show abstract